SECOND REGULAR SESSION
HOUSE BILL NO. 1830
102ND GENERAL ASSEMBLY
INTRODUCED BY REPRESENTATIVE MCMULLEN.
4258H.01I DANARADEMANMILLER,ChiefClerk
AN ACT
To repeal section 191.480, RSMo, and to enact in lieu thereof three new sections relating to
alternative therapies.
Be it enacted by the General Assembly of the state of Missouri, as follows:
SectionA. Section191.480,RSMo,isrepealedandthreenewsectionsenactedinlieu
2 thereof, to be known as sections 191.479, 191.480, and 192.950, to read as follows:
191.479. 1. As used in this section, the term "bona fide physician-patient
2 relationship" means a relationship between a physician and a patient in which the
3 physician:
4 (1) Has completed an assessment of the patient's medical history and current
5 medical condition, including an in-person examination of the patient;
6 (2) Has consulted with the patient with respect to the patient's medical
7 condition; and
8 (3) Is available to provide follow-up care and treatment to the patient.
9 2. Notwithstandingtheprovisionsofchapter195or579oranyotherprovisionof
10 law to the contrary, any person who acquires, uses, produces, possesses, transfers, or
11 administers psilocybin for the person's own therapeutic use shall not be in violation of
12 state or local law and shall not be subject to a civil fine, penalty, or sanction so long as
13 the following conditions are met:
14 (1) The person is twenty-one years of age or older;
15 (2) The person suffers from posttraumatic stress disorder, major depressive
16 disorder, or a substance use disorder or requires end-of-life care;
17 (3) The person:
EXPLANATION â€” Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is
intended to be omitted from the law. Matter in bold-face type in the above bill is proposed language.
HB 1830 2
18 (a) Has enrolled in a clinical trial to study the use of psilocybin to treat
19 posttraumatic stress disorder, major depressive disorder, or substance use disorders or
20 for end-of-life care; or
21 (b) Sought to enroll in a clinical trial described in paragraph (a) of this
22 subdivision but was declined due to lack of space or lack of existing clinical trials for
23 which the person was eligible;
24 (4) The person informs the department of health and senior services that the
25 person plans to acquire, use, produce, possess, transfer, or administer psilocybin in
26 accordance with this section;
27 (5) The person provides the department of health and senior services with:
28 (a) Documentation from a physician with whom the patient has a bona fide
29 physician-patient relationship that the person suffers from posttraumatic stress
30 disorder, major depressive disorder, or a substance use disorder or requires end-of-
31 life care;
32 (b) The name of an individual who will be present with the person when the
33 person uses psilocybin. Such individual shall be:
34 a. Licensed as a physician;
35 b. Licensed as a therapist; or
36 c. Licensed by the federal government or another government entity in the
37 therapeutic use of psilocybin;
38 (c) The address of the location where the use of psilocybin will take place; and
39 (d) The time period, not to exceed twelve months, during which the person will
40 use psilocybin;
41 (6) The person ensures that a laboratory licensed by the state to test controlled
42 substances tests the psilocybin the person intends to ingest; and
43 (7) The person limits the use of psilocybin to no more than one hundred fifty
44 milligrams of psilocybin analyte (4-phosphoryloxy-N, N-dimethyltryptamine) during
45 any twelve-month period.
46 3. Notwithstandingtheprovisionsofchapter195or579oranyotherprovisionof
47 law to the contrary:
48 (1) Any person twenty-one years of age or older who assists another person in
49 anyoftheactsallowed undersubsection 2ofthissectionshallnotbeinviolation ofstate
50 or local law and shall not be subject to a civil fine, penalty, or sanction; and
51 (2) Any laboratory licensed by the state to test controlled substances orcannabis
52 that tests psilocybin for a person engaged in acts allowed under subsection 2 of this
53 section shall not be in violation of state or local law and shall not be subject to a civil
54 fine, penalty, or sanction.
HB 1830 3
55 4. Subject to appropriation, the department of health and senior services shall
56 provide grants totaling two million dollars for research on the use and efficacy of
57 psilocybin for persons described in subsection 2 of this section.
58 5. The department of health and senior services shall prepare and submit to the
59 governor, lieutenant governor, and the general assembly annual reports on any
60 informationcollected bythedepartmenton theimplementation andoutcomes oftheuse
61 of psilocybin as described in subsection 2 of this section.
62 6. The department of health and senior services shall maintain the
63 confidentiality of any personally identifiable protected information collected from any
64 persons who provide information to the department under subsection 2 of this section.
65 7. Notwithstanding anyotherprovisionoflawtothecontrary,thedepartmentof
66 health and senior services, any health care providers, and any other person involved in
67 the acts described in subsection 2 of this section shall not be subject to criminal or civil
68 liabilityorsanctionunderthelawsofthisstateforprovidingcaretoapersonengagedin
69 acts allowed under subsection 2 of this section, except in cases of gross negligence or
70 willful misconduct. No health care provider shall be subject to discipline against his or
71 her professional license for providing care to a person engaged in acts allowed under
72 subsection 2 of this section.
73 8. Notwithstanding any other provision of law to the contrary, a physician shall
74 not be subject to criminal or civil liability or sanction under the laws of this state for
75 providing documentation that a person suffers from posttraumatic stress disorder,
76 major depressive disorder, or a substance use disorder or requires end-of-life care, and
77 no state agency or regulatory board shall revoke, fail to renew, or take any other action
78 against a physician's license issued under chapter 334 based solely on the physician's
79 provision of documentation that a person suffers from posttraumatic stress disorder,
80 major depressive disorder, or a substance use disorder or requires end-of-life care.
81 9. Notwithstandinganyotherprovisionoflawtothecontrary,nostateagencyor
82 employee of a state agency shall disclose to the federal government, any federal
83 government employee, or any unauthorized third party the statewide list or any
84 individual information of persons who meet the requirements of this section.
191.480. 1. For purposes of this section, the following terms shall mean:
2 (1) "Eligible patient", a person who meets all of the following:
3 (a) Has a terminal condition or illness, a life-threatening condition or illness, or a
4 severely debilitating condition or illness;
5 (b) Has considered all other treatment options currently approved by the United
6 States Food and Drug Administration and all relevant clinical trials conducted in this state;
HB 1830 4
7 (c) Has received a prescription or recommendation from the person's physician for an
8 investigational drug, biological product, or device;
9 (d) Has given written informed consent which shall be at least as comprehensive as
10 the consent used in clinicaltrials for the use of the investigational drug, biological product, or
11 device or, if the patient is a minor or lacks the mental capacity to provide informed consent, a
12 parent or legal guardian has given written informed consent on the patient's behalf; and
13 (e) Has documentation from the person's physician that the person has met the
14 requirements of this subdivision;
15 (2) "Investigationaldrug,biologicalproduct,ordevice",adrug,biologicalproduct,or
16 device, any of which are used to treat the patient's terminal condition or illness, life-
17 threatening condition or illness, or severely debilitating condition or illness, that has
18 successfully completed phase one of a clinical trial but has not been approved for general use
19 by the United States Food and Drug Administration and remains under investigation in a
20 clinical trial[. The term shall not include Schedule I controlled substances];
21 (3) "Life-threatening condition or illness", a disease or condition:
22 (a) In which the likelihood of death is high unless the course of the disease is
23 interrupted; and
24 (b) With potentially fatal outcomes, where the end point of clinical trial analysis
25 is survival;
26 (4) "Severely debilitating condition or illness", a disease orcondition that causes
27 major irreversible morbidity;
28 (5) "Terminal condition or illness", a disease that without life-sustaining procedures
29 will result in death in the near future or a state of permanent unconsciousness from which
30 recovery is unlikely.
31 2. A manufacturer of an investigational drug, biological product, or device may make
32 available the manufacturer's investigational drug, biological product, or device to eligible
33 patients under this section. This section does not require that a manufacturer make available
34 an investigational drug, biological product, or device to an eligible patient. A manufacturer
35 may:
36 (1) Provideaninvestigationaldrug,biologicalproduct,ordevicetoaneligiblepatient
37 without receiving compensation; or
38 (2) Require an eligible patient to pay the costs of or associated with the manufacture
39 of the investigational drug, biological product, or device.
40 3. This section does not require a health care insurer to provide coverage for the cost
41 of any investigational drug, biological product, or device. A health care insurer may provide
42 coverage for an investigational drug, biological product, or device.
HB 1830 5
43 4. This section does not require the department of corrections to provide coverage for
44 the cost of any investigational drug, biological product, or device.
45 5. Notwithstanding any other provision of law to the contrary, no state agency or
46 regulatory board shall revoke, fail to renew, or take any other action against a physician's
47 license issued under chapter 334 based solely on the physician's recommendation to an
48 eligiblepatientregardingprescriptionforortreatmentwithaninvestigationaldrug,biological
49 product,ordevice. Actionagainstahealthcareprovider'sMedicarecertificationbasedsolely
50 on the health care provider's recommendation that a patient have access to an investigational
51 drug, biological product, or device is prohibited.
52 6. Ifaprovisionofthissectionoritsapplicationtoanypersonorcircumstanceisheld
53 invalid, the invalidity does not affect other provisions or applications of this section that can
54 be given effect without the invalid provision or application, and to this end the provisions of
55 this section are severable.
56 7. If the clinical trial is closed due to lack of efficacy or toxicity, the drug shall not be
57 offered. Ifnoticeisgivenonadrug,product,ordevicetakenbyapatientoutsideofaclinical
58 trial, the pharmaceutical company or patient's physician shall notify the patient of the
59 information from the safety committee of the clinical trial.
60 8. Except in the case of gross negligence or willful misconduct, any person who
61 manufactures, imports, distributes, prescribes, dispenses, or administers an investigational
62 drug or device to an eligible patient [with a terminal illness] in accordance with this section
63 shall not be liable in any action under state law for any loss, damage, or injury arising out of,
64 relating to, or resulting from:
65 (1) The design, development, clinical testing and investigation, manufacturing,
66 labeling, distribution, sale, purchase, donation, dispensing, prescription, administration, or
67 use of the drug or device; or
68 (2) The safety or effectiveness of the drug or device.
192.950. 1. Notwithstandingtheprovisionsofchapter195or579tothecontrary,
2 the department of health and senior services, in collaboration with a hospital operated
3 byaninstitutionofhighereducationinthisstateorwithcontractresearchorganizations
4 conducting trials approved by the United States Food and Drug Administration, shall
5 conduct a study on the efficacy of using alternative medicine and therapies, including
6 the use of psilocybin, in the treatment of patients who suffer from posttraumatic stress
7 disorder, major depressive disorder, or substance use disorders or who require end-of-
8 life care.
9 2. (1) In conducting the study, the department of health and senior services, in
10 collaboration with the hospital or contract research organizations described in
11 subsection 1 of this section and subject to appropriations, shall:
HB 1830 6
12 (a) Perform a clinical trial on the therapeutic efficacy of using psilocybin in the
13 treatment of patients who suffer from posttraumatic stress disorder, major depressive
14 disorder, or substance use disorders or who require end-of-life care; and
15 (b) Review current literature regarding:
16 a. The safety and efficacy of psilocybin in the treatment of patients who suffer
17 from posttraumatic stress disorder, major depressive disorder, or substance use
18 disorders or who require end-of-life care; and
19 b. The access that patients have to psilocybin for such treatment.
20 (2) The departmentof health andsenior servicesshall prepareand submitto the
21 governor, lieutenant governor, and the general assembly the following:
22 (a) Quarterly reports on the progress of the study; and
23 (b) A written report, submitted one year following the commencement of the
24 study, which shall:
25 a. Contain the results of the study and any recommendations for legislative or
26 regulatory action; and
27 b. Highlight those clinical practices that appear to be most successful as well as
28 any safety or health concerns.
29 3. The department of health and senior services shall maintain the
30 confidentiality of any personally identifiable protected information collected during
31 the clinical trial under this section.
32 4. Notwithstanding anyotherprovisionoflawtothecontrary,thedepartmentof
33 health and senior services, any health care providers, and any other person involved in
34 the clinical trial under this section shall not be subject to criminal or civil liability or
35 sanctionunderthelawsofthisstateforparticipatinginthetrial,exceptincasesofgross
36 negligence or willful misconduct. No health care provider shall be subject to discipline
37 against his or her professional license for participation in the trial.
38 5. Notwithstanding any other provision of law to the contrary, a physician shall
39 not be subject to criminal or civil liability or sanction under the laws of this state for
40 referring a patient to the clinical trial under this section, and no state agency or
41 regulatory board shall revoke, fail to renew, or take any other action against a
42 physician's license issued under chapter 334 based solely on the physician's referral of a
43 patient to the clinical trial under this section.
âœ”